Bionano Genomics (BNGO)
(Real Time Quote from BATS)
$0.44 USD
-0.04 (-8.31%)
Updated Sep 12, 2024 11:26 AM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BNGO 0.44 -0.04(-8.31%)
Will BNGO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNGO
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Other News for BNGO
BTIG downgrades Bionano to Neutral after fourth workforce reduction
BTIG gets more bearish on Bionano Genomics, downgrades shares
Bionano lowered 2024 revenue outlook to $32M-$36M from $36M-$40M
Bionano Genomics announces departure of CFO Gulsen Kama
Bionano Genomics lays off 45% of staff, or 84 employees